Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s stock price was up 7.3% on Wednesday . The stock traded as high as $8.70 and last traded at $8.88. Approximately 52,803 shares traded hands during trading, a decline of 92% from the average daily volume of 678,284 shares. The stock had previously closed at $8.27.

Wall Street Analyst Weigh In

A number of research analysts recently commented on XNCR shares. William Blair began coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and an average price target of $28.00.

Xencor Trading Up 11.6%

The company has a market capitalization of $656.90 million, a P/E ratio of -3.00 and a beta of 0.85. The stock has a 50 day moving average of $8.61 and a 200-day moving average of $13.13. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.16.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The firm had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The company's revenue for the quarter was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.11) earnings per share. On average, research analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Buying and Selling

In related news, Director Richard J. Ranieri sold 2,993 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kurt A. Gustafson sold 2,993 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director owned 20,183 shares in the company, valued at $186,087.26. This trade represents a 12.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,810 shares of company stock valued at $154,123 over the last 90 days. Insiders own 5.23% of the company's stock.

Institutional Investors Weigh In On Xencor

Large investors have recently bought and sold shares of the business. Sterling Capital Management LLC increased its holdings in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor during the 4th quarter worth approximately $34,000. State of Wyoming bought a new position in Xencor in the 1st quarter valued at approximately $34,000. CWM LLC increased its position in shares of Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 2,231 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,337 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.